A possible therapeutic agent was rituximab, but trials have shown conflicting evidence regarding its effectiveness5. [...]there is a need for an alternative treatment that can circumvent the current treatment limitations. IGF-IR and TSHR also form a receptor complex that when activated causes the activation of both receptors3. Because IGF-IR antibodies have been shown to mitigate the TSHR antibodies, blocking the stimulation of IGF-IR disrupts the pathway for the orbital tissues expansion of TED3.Therefore, due to its potential role in the pathogenesis of TED, treatment with a human IGF-IR monoclonal antibody, teprotumumab, was proposed. [...]the double-masked, randomized, multicenter, placebo-controlled trial by Smith et. al demonstrated that a 24-week course of teprotumumab benefits patients with moderate to severe Graves ophthalmopathy by enhancing quality of life as well as reducing their Clinical Activity Score and proptosis3.